Predicting response to enzalutamide and abiraterone in metastatic prostate cancer using whole-omics machine learning.

Nat Commun · 2023 · PMC10082805 · PMID 37031196

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Poor responders showed a trend towards a higher proportion of biopsies, obtained from liver, compared to good responders (18.8% ( n = 12) versus 3.0% ( n = 2), q = 0.076 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.